Georgiamune
Georgiamune is a United States-based biotechnology company running 2 late-stage cancer trials of GIM122 and GIM-531 in melanoma.
Overview
Georgiamune, based in Gaithersburg, the United States, is a biotechnology company. Georgiamune develops immunotherapies that reprogram immune signalling pathways to rebalance immune system components, for cancer and autoimmune disease. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing GIM122 and GIM-531 in melanoma. The largest, NCT06425926 (Safety and Tolerability Study of GIM-531 in Advanced Solid Tumours), plans to enrol 117 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyKrystal Biotech
Shares Melanoma and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Melanoma and the tag ctgov-sponsor.
- CompanyAura Biosciences
Shares Melanoma and the tag ctgov-sponsor.
- CompanyMultitude Therapeutics
Shares Melanoma and the tag ctgov-sponsor.
- CompanyHangzhou Hanx Biopharmaceuticals
Shares Melanoma and the tag ctgov-sponsor.
- CompanyiOnctura
Shares Melanoma and the tag ctgov-sponsor.
- CompanyShanghai Kechow Pharma
Shares Melanoma and the tag ctgov-sponsor.
- CompanyShanghai Juncell Therapeutics
Shares Melanoma and the tag ctgov-sponsor.